XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash flows provided by operating activities:            
Net income $ 197,128   $ 163,665 $ 531,476 $ 395,917  
Adjustments to reconcile net income to net cash provided by operating activities:            
Depreciation and amortization expense       391,845 436,217  
Impairment of operating right-of-use assets and related property, plant and equipment       12,559 8,845  
Reduction in carrying value of operating right-of-use assets       29,820 33,979  
Loss on equity method investments 0   0 0 383  
Acquisition-related gain       0 (6,160)  
Amortization of financing costs and debt discount       22,066 12,485  
Stock compensation expense       41,183 47,303  
Deferred tax benefit       (86,579) (114,487)  
Unrealized foreign exchange movements       34,018 (7,670)  
Other non-cash items       26,828 21,966  
Changes in operating assets and liabilities:            
Accounts receivable       352,795 (139,096)  
Unbilled revenue       (423,533) 14,370  
Unearned revenue       (72,930) 158,269  
Other net assets       88,790 (141,425)  
Net cash provided by operating activities       948,338 720,896  
Cash flows used in investing activities:            
Purchase of property, plant and equipment       (106,772) (87,980)  
Purchase of subsidiary undertakings (net of cash acquired)       (85,629) (5,100)  
Payments for (Proceeds from) Short-Term Investments       1,954 (241)  
Proceeds from investments in equity       2,671 0  
Purchase of investments in equity       (10,131) (10,829)  
Net cash used in investing activities       (197,907) (104,150)  
Cash flows used in financing activities:            
New Notes issue costs       (12,678) 0  
Drawdown of credit lines and loan facilities       2,242,480 305,000  
Repayment of credit lines and loan facilities       (2,595,323) (930,000)  
Proceeds from exercise of equity compensation       32,379 36,517  
Share issue costs       (17) (14)  
Repurchase of ordinary shares       (100,000) 0  
Share repurchase costs       (68) 0  
Net cash used in financing activities       (433,227) (588,497)  
Effect of exchange rate movements on cash       201 (3,952)  
Net increase in cash and cash equivalents       317,405 24,297  
Cash and cash equivalents at beginning of period   $ 313,065   378,102 288,768 $ 288,768
Cash and cash equivalents at end of period $ 695,507 $ 378,102 $ 313,065 $ 695,507 $ 313,065 $ 378,102